New pharma
Follow
Find
6.2K views | +3 today
New pharma
Pharma's struggle for a new commercial model
Curated by rob halkes
Your new post is loading...
Your new post is loading...
Scooped by rob halkes
Scoop.it!

How Sanofi Is Writing The Social Media Rules For Big Pharma Without Running Afoul Of The FDA

How Sanofi Is Writing The Social Media Rules For Big Pharma Without Running Afoul Of The FDA | New pharma | Scoop.it
The biggest challenge to treating patients with diabetes isn’t doling out medications, it's making sure that people control their habits. Poor diet and lack of exercise generally create complications with the disease.
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Who Should Life Science Pros Follow on Twitter? | Xconomy

Who Should Life Science Pros Follow on Twitter? | Xconomy | New pharma | Scoop.it

Luke Tiimer man states: Last week, I made a case that Twitter has begun to come of age in biotech, and it’s now a must-read source of real-time industry news and information.

Here's his list of all the people he selected to be worthwhile to follow.

See and decide!

But thing is: pharma, biotech and life sciences are on the social site of the business! Be there with them.

more...
No comment yet.
Rescooped by rob halkes from Pharma
Scoop.it!

Innovation: the name of the game for Boehringer

Innovation: the name of the game for Boehringer | New pharma | Scoop.it

Andrew Spong (@andrewspong) writes:

 

'By dint of the sheer weight of evidence that has accrued over the past three years alone, Boehringer Ingelheim may reasonably be identified as the pharma company that sets the pace for the industry in digital environments.

 

However, this is not because of Boehringer’s having led the way on facebook with regard to its handling of comments, nor its conversational disposition on Twitter, nor its experiments in the gamification of clinical research, nor the way it used social to raise awareness around atrial fibrillation, nor its experiments with outré humour.

 

It is not even because later this week Boehringer will become the first pharma company to launch a game which has been designed first and foremost to be fun and perhaps convey some indirect benefits, rather than a vehicle built for the primary purpose of delivering a direct message:

 

[Syrum] wasn’t built with a view to being an educational platform or anything like that. It’s very much a game which is meant to be engaging and entertaining to play. In the same way that Farmville doesn’t just appeal to people who like farms, Syrum isn’t just for people who like the pharmaceutical industry. It’s for anyone to play. John Pugh, Director of Digital, Boehringer Ingelheim

 

In the last instance, Boehringer merits recognition as the digital leader in the pharma industry not because of what it has achieved, but because of what its activities say about the cultural evolution that has taken place within the company. Boehringer’s every action speaks of its commitment to embodying what ‘being innovative’ means. Not its just giving lip-service to innovation. Not its hoping to be seen to be innovative whilst doing little of real merit. Not spending its time considering which ride to take next on the platform carousel.

 

The course that Boehringer has steered over the past three years marks it out as a company that aspires to being a leading company in digital environments, not just the leading pharma company in digital.'

 

[AS: Click on the title link above to read the full article]


Via Andrew Spong
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

The Blockbuster Drug of the Century: An Engaged Patient

The Blockbuster Drug of the Century: An Engaged Patient | New pharma | Scoop.it
Patient engagement sounds like a utopian, out-of-touch goal of Meaningful Use. But there is truth in numbers, and they show that engagement is a must.

Healthcare must be built on a foundation of Health IT-supported care coordination and patient engagement, there is no other way to consistently and quickly scale improvements and care, and to accelerate the overall learning of the health care system.

As Topol points out, this is the path to real, personalized medicine, and away from the population-based studies and results that we’ve seen...

 

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

WIll pharma marketing become de facto multichannel marketing in the future

WIll pharma marketing become de facto multichannel marketing in the future | New pharma | Scoop.it

WIll pharma marketing become de facto multichannel marketing in the future?

 

In the future?  uh...

See the results form the poll initated by @lenstarnes

Inspiring responses.

Don't you think too, that pharma marketing in relatiy is always one step behind to where it should be? Well, it is a difficult task, inchaing market conditions and with internal cutbacks to change and develop..

I do understand, but can I approve this lacking behind?

Can you?

;-)

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Q&A with Dominique Hind- Owner and Director of WiTH Collective- Social Media and what ALL Australian businesses need to realise - DigiPharm - Digital Marketing Strategies for Pharmaceutical Products

Q&A with Dominique Hind- Owner and Director of WiTH Collective- Social Media and what ALL Australian businesses need to realise - DigiPharm - Digital Marketing Strategies for Pharmaceutical Products | New pharma | Scoop.it

excerpt: Q&A with Dominique Hind What is the most important change to marketing over the last 5 years? Dominique: The adoption of social media and the seismic change that it has brought to digital behaviours, communications..

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Why drug companies need to build their own web communities | World of DTC Marketing.com

Why drug companies need to build their own web communities | World of DTC Marketing.com | New pharma | Scoop.it
People love to help each other online and they are turning to branded websites to get information so why the focus on social media when there is communities...
more...
No comment yet.
Rescooped by rob halkes from Pharma
Scoop.it!

IBM's reinvention should inspire flat pharma businesses

IBM's reinvention should inspire flat pharma businesses | New pharma | Scoop.it

The pharmaceutical giants look remarkably similar to the IBM of the late 80′s and early 90′s.

 

For those of us who remember the IBM of that era, this is bad news.

 

They can continue the path of the railroad industry early in the 20th century. Alternatively, they can look to the path IBM took when its future prospects were grim.

 

Remarkably, IBM demonstrated how it’s possible for a large company to shift from a product-centric culture to a customer and service centered company.

 

The writing is on the wall for pharma companies: they will succeed or fail based not on how many drugs they sell, but on how well their offerings improve health outcomes.


Via Andrew Spong
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Drug pipelines improving after years in doldrums | FirstWord Pharma

Drug pipelines improving after years in doldrums | FirstWord Pharma | New pharma | Scoop.it

Drug pipelines improving after years in doldrums:

- According to data from Thomson Reuters, drug industry productivity is improving after years of research disappointment, as drugmakers shift their focus from blockbuster drugs to making medicines for rare diseases, as reported Tuesday on Yahoo!News.

-"There has clearly been a downward trend in R&D efficiency in the past but what we are seeing now are some indicators that may be reversing," said Chris McKenna, vice-president for professional services at Thomson Reuters Life Sciences.

"New molecular entity output is improving and the number of projects going into clinical development is declining, which indicates the industry is moving away from a numbers game and is focusing on better-quality candidates ... we probably need a couple more years to see if it is a sustained pattern," McKenna added.

 

 

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

TechCrunch | Pharma’s Huge Threat (and Opportunity): mRx

TechCrunch | Pharma’s Huge Threat (and Opportunity): mRx | New pharma | Scoop.it
It was only a matter of time before healthcare providers would start prescribing mHealth apps as soon as they proved to be as or more effective than prescription drugs.

Smart pharma will become players, not just spectators in industry disruption..

It seems that a day doesn’t go by where I don’t hear about some pharma sponsored “app challenge.”

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Devices Diagnostics The App AvantGarde

Devices  Diagnostics The App AvantGarde | New pharma | Scoop.it
Medical devices that are part app, part consumer gadget are spurring changes.

It also suits the pharmaceutical industry's shift toward a more diversified offering featuring not just drugs and biologics but also diagnostics, devices and services, bundled together to give their therapies an edge with increasingly powerful and tightfisted payers..

“Doctor-patient facetime is where most pharmaceutical products focus their marketing efforts,” says HAVAS Health chief digital officer Larry Mickelberg. “Now they've got to think about the in-between time, and that's where innovation is going to happen. It's a characteristic difference between the old healthcare mindset and the way things are moving, and that means rather than periodic exchanges of information between doctor and patient during scheduled visits, all parties can now consult and exchange information in a continuum across multiple channels.”

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Working Life: Jane Griffiths - InPharm

Working Life: Jane Griffiths - InPharm | New pharma | Scoop.it

Working Life: Jane GriffithsInPharmI joined Janssen, the pharmaceutical division of Johnson & Johnson, as a sales representative after completing my PhD at the University of Aberystwyth in 1982.

...Now we follow the product in the real patient environment. Health literacy, adherence and patient responsibility are essential to increasing therapeutic effectiveness. Luckily, in today’s world, the patient is an informed participant, and this is also changing the dynamic of healthcare. Rather than simply providing safe and efficacious products, we need to provide healthcare and health services that go beyond the disease, supporting the quality of life of the whole person....

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

My Cancer Circle – Cancer Support Community for Patients and Caregivers

My Cancer Circle – Cancer Support Community for Patients and Caregivers | New pharma | Scoop.it
Visit the My Cancer Circle support group for stories, message boards and other resources for cancer patients, caregivers and family members.
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Rx adherence better when docs share notes: study | Healthcare business news, research and events from Modern Healthcare

Rx adherence better when docs share notes: study | Healthcare business news, research and events from Modern Healthcare | New pharma | Scoop.it

Rx adherence better when docs share notes: study |

 

Most physicians who let patients read their notes over the course of a year as part of a study concluded that the practice was a good idea, and most patients in the study said the experience increased their medication adherence, according to a report in the Annals of Internal Medicine.

 

more...
No comment yet.
Rescooped by rob halkes from Digital Pharma
Scoop.it!

Boehringer Ingelheim launches beta social game Syrum to promote science and innovation

Boehringer Ingelheim launches beta social game Syrum to promote science and innovation | New pharma | Scoop.it
Boehringer Ingelheim has announced the beta launch of its first social game on Facebook, called Syrum. Syrum will be a new and evolving platform for the research-driven pharmaceutical company to inspire and educate in a changing digital world. In development for more than two years, Syrum has been specifically designed to demonstrate the complex processes around medicine research and development through gaming mechanics. It aims at promoting science and innovation to the digital community in a fun and engaging way.


"The use of gaming in education has been put to effective use all over the world as more organisations appreciate that humans are better motivated and stimulated by interaction, fun and engagement", says Dr Jez Rose, behavioural psychologist from Buckinghamshire, United Kingdom. "Syrum is a fantastic example of how fun gaming can be used to provide educational delivery, whilst maintaining interest and engagement through a logical, platform learning style."

 

Syrum allows players to create and run their own pharmaceutical company, using a virtual laboratory to discover and develop imaginary medicines to improve the health of the world. Molecular compounds can be developed and then traded with other players. In each ‘chapter’, the player has to solve a particular problem, whether a disease or a pandemic. The goal is to discover cures by first creating a stable medicine, conducting a clinical trial and finally bringing the medicine to the market.

 

"The research driven pharmaceutical industry is immersed in education - whether aimed at medical or pharmaceutical professionals or providing information directly to the public," says John Pugh, Director of Digital at Boehringer Ingelheim. "Gaming is an experimental way for Boehringer Ingelheim to do this. The challenge is to do this in a truly engaging, educational and entertaining way that immerses the player."

 

Syrum is built on Facebook, and has already generated a high level of interest, both within the pharmaceutical industry and amongst gamers. More than 1,000 people have already signed up to play in advance of the launch via the website www.syrum-game.com.

The game is launched first in a beta format outside the US and Canada to actively encourage feedback from the players and will be constantly developed based on the players’ ideas and thoughts.

 

The official global launch of Syrum is planned for 2013.


Via Thibaud Guymard
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Survey Results abt Pharma correcting Wikipedia's misinformations

About the question wether "Pharma" should correct wikipedia's "misinformations": Only 6.8% agree in @pharmaguy's survey

via @farmerfunster

@soulflsepulcher Re Wikipedia editing in #socpharm @cadelarge tweetup see @pharmaguy survey http://t.co/LYdaunIv & #hcsmeu tweetup Q1 15-Jun

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

IBM 2012 Global CEO Study

IBM 2012 Global CEO Study | New pharma | Scoop.it

IBM Studying CEO's opinions:

By analyzing findings of interviews with over 1,700 CEOs worldwide, the fifth biennial IBM Global CEO Study, “Leading Through Connections,” reveals how CEOs are prioritizing the creation of more impactful connections with their employees, customers and partnerships!

In speaking face-to-face with 1,709 CEOs, general managers and senior public sector leaders around the globe, leaders confirmed that our new connected era is changing how people engage.

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

FDA Approves First-Ever Digestible Microchip

FDA Approves First-Ever Digestible Microchip | New pharma | Scoop.it
The FDA has approved the first digestible microchip for humans. Proteus Digital Health has created a chip that’s safe to embed in a number of pharmaceuticals.
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Pharma and healthcare innovation: ten steps forward

Pharma and healthcare innovation: ten steps forward | New pharma | Scoop.it

If one takes a long view of the history of technological innovation in business, a pattern can be perceived.

How could one use those patterns to initate a series of tactics to create an innovative attitude and actual developments?

10 Hinta by Andrew Spong

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Pharma digital marketing: Targeting opportunities | World of DTC Marketing.com

Pharma digital marketing: Targeting opportunities | World of DTC Marketing.com | New pharma | Scoop.it

Though pharma is not allowed in Europe to (digitally) market to consumers, marketeers might benefit from fenerla insights into profiles of consumers interested in pharma ads in the States.

These insights may give them information to use to inform doctors. However, by listening and reading patients' conversations on line in Europe itself, they might learn the best!

By broadening targeting opportunities pharma marketers can increase the reach of their direct to consumer online ads.

more...
No comment yet.
Rescooped by rob halkes from Ideagoras
Scoop.it!

Overcoming pharma's lack of digital regulations - Digital Handbook - Regulatory issues

Overcoming pharma's lack of digital regulations - Digital Handbook - Regulatory issues | New pharma | Scoop.it
The industry does have regulations that cover digital marketing, but much rests on interpretation - PMLiVE...

Via Angel Gonzalez
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Pharmaceuticals Executive Survey: Executives Seek M&A to S | KPMG | US

Pharmaceuticals Executive Survey: Executives Seek M&A to S | KPMG | US | New pharma | Scoop.it

Pharmaceuticals Executive Survey:

KPMG's results from 2011 Pharmaceutical Pulse survey:

- M&A activity is expected to heat up in the sector over the next two years;

- Pharmaceutical executives are not expecting a full economic recovery for a few years;

- Growth in foreign markets is seen as an increasing area of importance;

- Headcount is down significantly from a year ago;

- The majority of pharmaceutical industry executives say that U.S. healthcare reform legislation is not addressing the real challenges for U.S. healthcare (63 percent)..

 

Investment priorities were to be seen in, a.o.:

- Acq of business: 40%;

- New products or services: 38%;

- Business model transformation: 19%..

 

Industry challenges

Looking forward, pharmaceutical executives view external factors with much greater concern than internal factors. A large majority of executives (76 percent) admitted being concerned about the economy, competition, and the impact of regulatory changes compared to their ability to compete or whether they have the right strategic direction internally (24 percent).

In addition, it is not surprising that sector executives identified regulatory and legislative pressures (60 percent) as the most significant barrier to growth over the next year, followed by pricing pressures (55 percent).

 

 

Original data at KPMG's site - not rewritten text by review sites (stating it was data from 2012!)..

more...
No comment yet.
Rescooped by rob halkes from Pharma
Scoop.it!

IBM tell pharma: Having a presence on social media sites is not equivalent to 'using social media'

IBM's recommendations to pharma include:

 

* Provide more information on drugs, medication and supporting services to a targeted audience

* Provide information about research on new drugs to the general community

* Educate the community about health issues/awareness and treatment

* Deepen the connection with groups of patients and healthcare professionals through unbranded presences

* Provide information on drug recalls more rapidly and to a wider audience than currently is the case


Via Andrew Spong
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Pharma rocks many Twitter handles for many reasons - FierceBiotech IT

Pharma rocks many Twitter handles for many reasons - FierceBiotech IT | New pharma | Scoop.it
Pharma rocks many Twitter handles for many reasons

The Twittersphere is lousy with pharma feeds. Count them up, as Eye on FDA recently did, and 44 drugmakers operate 200 Twitteraccounts, and the number appears to be growing as pharma companies raise their online profiles and tailor their social media strategies.

Yet there are gray areas around how to operate in the realm of the social web, calling for careful stewardship of Twitter accounts and Facebookpages, where the possibility exists for companies to have their products and profiles dragged through the digital mud...

more...
No comment yet.